Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites
of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with …

Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …

Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL),
a potentially fatal disease caused by infection with Leishmania parasites. In the current …

Visceral leishmaniasis (VL) or kala-azar, a vector-borne protozoan disease, shows
endemicity in larger areas of the tropical, subtropical and the Mediterranean countries. WHO …

Developing vaccines for livestock provides researchers with the opportunity to perform
efficacy testing in the natural hosts. This enables the evaluation of different strategies …

The protozoan parasite Leishmania donovani, residing and replicating within the cells of the
monocyte-macrophage (mono-mac) lineage, causes visceral leishmaniasis (VL) in humans …

Although there has been an extensive research on vaccine development over the last
decade and some vaccines have been commercialized for canine visceral leishmaniasis …

We have previously shown that a novel DNA vaccine technology of codon optimization and
the addition of ubiquitin sequences enhanced immunogenicity of a herpes simplex virus 2 …

The visceral leishmaniasis (VL) caused by Leishmania donovani parasite severely affects
large populations in tropical and subtropical regions of the world. The arsenal of drugs …

Visceral leishmaniasis (VL) caused by Leishmania donovani and Leishmania
infantum/chagasi represents the second most challenging infectious disease worldwide …